GT Biopharma Story

<div class='circular--portrait' style='background:#FF6600;color: #FFF8DC;font-size:4em;'>GB</div>
GTBP -- USA Stock  

USD 9.13  0.50  5.19%

GT Biopharma Net Cash Flow from Financing is very stable at the moment as compared to the past year. GT Biopharma reported last year Net Cash Flow from Financing of 3.94 Million. As of 28th of March 2021, Net Cash Flow from Investing is likely to grow to about 248.2 K, while Average Equity is likely to drop (5.3 M). While some baby boomers are getting worried about healthcare space, it is reasonable to recap GT Biopharma. Why are we still confident in hope for a quick recovery. Here I will also expose some primary fundamental factors affecting GT Biopharma's services, and outline how it will impact the outlook for investors this year.
Published over two weeks ago
View all stories for GT Biopharma | View All Stories
Another strong showing for GT Biopharma
Net Loss for the year was (14.83 M).

How important is GT Biopharma's Liquidity

GT Biopharma financial leverage refers to using borrowed capital as a funding source to finance GT Biopharma ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. GT Biopharma financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Please check the breakdown between GT Biopharma's total debt and its cash.

How GT Biopharma utilizes its cash?

To perform a cash flow analysis of GT Biopharma, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash GT Biopharma is receiving and how much cash it distributes out in a given period. The GT Biopharma cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.
GT Biopharma Net Cash Flow from Operations is very stable at the moment as compared to the past year. GT Biopharma reported last year Net Cash Flow from Operations of (3.29 Million)

What did GT Biopharma file with SEC?

The SEC filings are financial statements or other formal documents of GT Biopharma that are regularly submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make SEC filings and fintech professionals rely on these filings for information about companies they are evaluating for investment purposes. Please note, most SEC filings are available online through the SEC's EDGAR database.
Please check here for more information.
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to GT Biopharma shareholders may or may not be submitted as SEC does not always require it.
31st of March 2021
Other Events
View
22nd of February 2021
Financial Statements and Exhibits. Amendments to Articles of Incorporation or Bylaws; and/or Change in Fiscal Year. Unregistered Sales of Equity Securities
View
18th of February 2021
Unregistered Sales of Equity Securities
View
17th of February 2021
Unclassified Corporate Event. Unregistered Sales of Equity Securities
View
Please note, although all public domestic companies are required to submit their filings via EDGAR, not all public companies are available through our service. Also, keep in mind that the actual annual reports to GT Biopharma shareholders may or may not be submitted as SEC does not always require it.

Breaking down GT Biopharma Further

GT Biopharma secures a total of twenty-one million three hundred seventy thousand outstanding shares. GT Biopharma shows tangible amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how much assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Ownership Breakdown

Retail Investors
69.22%
Insiders
22.32%
Institutions
8.46%
Retail Investors69.22
Insiders22.32
Institutions8.46

Our perspective of the recent GT Biopharma roll up

Semi variance is down to 32.23. It may hint at a possible volatility decline. GT Biopharma is displaying above-average volatility over the selected time horizon. Investors should scrutinize GT Biopharma independently to ensure intended market timing strategies are aligned with expectations about GT Biopharma volatility. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure GT Biopharma's stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact GT Biopharma's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.

Our Final Perspective on GT Biopharma

Although many other companies under the biotechnology industry are still a bit expensive, GT Biopharma may offer a potential longer-term growth to insiders. With a relatively neutral outlook on the recent economy, it is better to hold off any trading of GT Biopharma as the current risk-reward utility is not appealing enough. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to GT Biopharma.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of GT Biopharma. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com